Autolus Therapeutics plc - American Depositary Share (AUTL) News
Filter AUTL News Items
AUTL News Results
|Loading, please wait...|
AUTL News Highlights
- For AUTL, its 30 day story count is now at 4.
- Over the past 15 days, the trend for AUTL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about AUTL are BIO, CABA and TCRT.
Latest AUTL News From Around the Web
Below are the latest news stories about AUTOLUS THERAPEUTICS PLC that investors may wish to consider to help them evaluate AUTL as an investment opportunity.
Here is how Alaunos (TCRT) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
LONDON, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces two changes to the company’s Board of Directors. The company’s non-executive Chairman, John H Johnson, who has held the role since September 2021, will not stand for re-election at Autolus’ upcoming annual shareholder meeting. During his tenure as Chairman of Autolus he was appointed as Chief Executive Offi
Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus’ Safety Switch System in Cell Therapies for Autoimmune Disease
LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into a non-exclusive license agreement with Cabaletta Bio, Inc (Nasdaq: CABA). The agreement allows Cabaletta to incorporate Autolus’ proprietary RQR8 safety switch1 into a cell therapy program for the treatment of autoimmune disease, with an option for Cabaletta to incorporate the
Individual investors account for 36% of Autolus Therapeutics plc's (NASDAQ:AUTL) ownership, while private equity firms account for 32%
If you want to know who really controls Autolus Therapeutics plc ( NASDAQ:AUTL ), then you'll have to look at the...
LONDON, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced today that the underwriters of its previously announced public offering of American Depositary Shares, or ADSs, which closed on December 13, 2022, have partially exercised their option to purchase an additional 6,927,102 ADSs, at a price per ADS of $2.00, resulting in additional gross proceeds to Autolus of
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
Obe-cel: 35% of relapsed/refractory adult B-ALL patients in the ALLCAR19 trial remain in complete remission at a median follow up of three years without the need for additional anti-leukemia therapy Obe-cel: continues to show high level of sustained clinical activity in B-NHL patientsAUTO1/22: no antigen negative relapse seen in responding patientsAUTO4: first sustained metabolic CRs at 9 and 12 months of follow-up in T cell Lymphoma patients LONDON, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Autolus The
The trading week is almost complete but we've still got the biggest pre-market stock movers to go over for Friday morning!
Shares of Autolus Therapeutics (NASDAQ: AUTL) were crashing 35.9% as of 10:34 a.m. ET on Friday. The steep decline came after the biopharmaceutical company announced the price of a public stock offering after the market closed on Thursday. Autolus said that it plans to offer 75 million American depositary shares (ADS) at a price of $2 each.
Autolus Therapeutics' Leukemia Trial Meets Primary Goal Of Remission Rate, Shares Fall After $150M Capital Raise
Autolus Therapeutics plc's (NASDAQ: AUTL) Phase 2 pivotal FELIX trial of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult Acute Lymphoblastic Leukemia (ALL) has met its primary endpoint of Overall Remission Rate (ORR). The data comes from a pre-planned interim analysis of 50 patients. The ORR for obe-cel was 70%. Obe-cel showed comparable expansion and initial persistence (median follow-up 6.4 months) to the data observed in the prior ALLCAR19 study. The safety analysis was b